Want to see IMNN full AI Analyst Report?
Top Page
Imunon
(NASDAQ:IMNN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-39.76% Downside)
Action:Reiterated
Date:09/29/26
The score is held down primarily by very weak financial performance (minimal revenue, sustained losses, and elevated TTM cash burn/debt) and bearish technical trend signals. The latest earnings call provides partial offset via positive clinical momentum and stronger-than-planned Phase III enrollment, but near-term financing needs remain a key constraint.
Positive Factors
Clinical efficacy signals
The substantial overall-survival improvements reported in OVATION II provide meaningful clinical validation for IMUNON-001 and could support broader adoption if confirmed. Durable efficacy evidence may strengthen the company’s partnering, regulatory, and commercial prospects as later-stage data mature.
Negative Factors
Near-term funding requirement
The limited runway and stated need for additional capital create a durable financing constraint while the company advances its pivotal program. Future fundraising could impose dilution, added obligations, or execution delays, making continued clinical progress dependent on successful capital access.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy signals
The substantial overall-survival improvements reported in OVATION II provide meaningful clinical validation for IMUNON-001 and could support broader adoption if confirmed. Durable efficacy evidence may strengthen the company’s partnering, regulatory, and commercial prospects as later-stage data mature.
Read all positive factors
Imunon (IMNN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.06M
Dividend YieldN/A
Average Volume (3M)135.14K
Price to Earnings (P/E)―
Beta (1Y)-0.95
Revenue GrowthN/A
EPS Growth71.67%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.53
Shares Outstanding5,611,403
10 Day Avg. Volume127,732
30 Day Avg. Volume135,144
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap1.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-61.82
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$15.67Price Target Upside843.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.52
Revenue Forecast (FY)N/A
Imunon Business Overview & Revenue Model
Company Description
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifi...
Imunon Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and translational momentum (robust Phase II OS gains, encouraging MRD signals, favorable safety) and operational execution (enrollment outperforming assumptions, cost discipline, recent financing), balanced against near-term financing needs and uncertainties tied to small MRD sample size and event-driven timing of Phase III interims. Overall the positives (clinical validation, enrollment traction, operational control) outweigh the negatives (short runway, need for additional capital, statistical limitations of MRD).Positive Updates
Compelling Phase II Overall Survival Gains
OVATION II demonstrated a 14.7-month median overall survival (OS) improvement (45.1 months vs 30.4 months), a +48.4% relative increase. Among patients receiving PARP inhibitor maintenance, OS improved by 24.2 months (65.6 months vs 41.4 months), a +58.5% relative increase. Company plans to present final OS data in early 2027.
Negative Updates
Limited Near-Term Cash Runway and Need for Additional Capital
Management believes current cash, plus the June financing and cost discipline, supports operations through year-end 2026, but additional capital will be required to support full execution of the Phase III trial and other needs. The $10 million financing may be insufficient for full Phase III funding and the company is actively exploring options.
Read all updates
Q2-2026 Updates
Positive
Negative
Compelling Phase II Overall Survival Gains
OVATION II demonstrated a 14.7-month median overall survival (OS) improvement (45.1 months vs 30.4 months), a +48.4% relative increase. Among patients receiving PARP inhibitor maintenance, OS improved by 24.2 months (65.6 months vs 41.4 months), a +58.5% relative increase. Company plans to present final OS data in early 2027.
Read all positive updates
Company Guidance
The company’s guidance emphasized continued rapid execution across clinical, operational and financial fronts: OVATION III enrollment is outpacing plan at ~0.5 patients/site/month (vs plan 0.3 and historical ~0.2), with ~35% of planned sites active or activating and roughly 2x the needed sites identified; interims are event‑driven and will follow full enrollment. Clinical readouts and validation remain strong: OVATION II showed a +14.7‑month median OS benefit (45.1 vs 30.4 months) and a +24.2‑month benefit with PARP inhibitor maintenance (65.6 vs 41.4 months); MRD trial preliminary data favored IMUNON on MRD positivity (44% vs 67%), ctDNA clearance (87.5% vs 62%) and no‑evidence‑of‑disease rates (100% vs 56%); safety to date shows no CRS, no systemic toxicities and no serious immune‑related AEs and the IDMC identified no new safety concerns. Financially, Q2 R&D was $1.5M (vs $1.2M LY), G&A $1.3M (down ~20% vs $1.6M LY), net cash used in operations was $3.0M in Q2 (vs $4.0M in Q1), cash was $6.9M as of 6/30/2026, and the company completed up to $10M financing in June (no warrants), supporting runway through year‑end while additional capital is being sought; near‑term event milestones include R&D Day on Sept 23, SITC Nov 2026 and planned presentation of final OS data in early 2027.Imunon Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 500.00K |
| Gross Profit | -166.54K | 0.00 | 0.00 | 0.00 | 500.00K | 500.00K |
| EBITDA | -13.97M | -13.80M | -17.90M | -19.88M | -31.71M | -20.88M |
| Net Income | -14.72M | -14.49M | -18.62M | -19.51M | -35.90M | -20.77M |
Balance Sheet | ||||||
| Total Assets | 14.99M | 12.29M | 9.72M | 21.92M | 43.98M | 74.05M |
| Cash, Cash Equivalents and Short-Term Investments | 6.86M | 8.78M | 5.87M | 15.70M | 32.75M | 49.39M |
| Total Debt | 7.85M | 1.01M | 1.14M | 1.62M | 6.27M | 6.63M |
| Total Liabilities | 10.80M | 5.23M | 5.47M | 8.53M | 14.65M | 18.25M |
| Stockholders Equity | 4.19M | 7.06M | 4.24M | 13.39M | 29.33M | 55.80M |
Cash Flow | ||||||
| Free Cash Flow | -4.07B | -14.18M | -18.88M | -19.47M | -23.36M | -16.54M |
| Operating Cash Flow | -4.00B | -13.90M | -18.85M | -19.02M | -23.10M | -16.22M |
| Investing Cash Flow | -69.08M | -280.57K | 9.83M | 11.01M | 8.28M | -30.12M |
| Financing Cash Flow | 11.02B | 17.09M | 9.06M | -3.64M | 6.72M | 54.77M |
Imunon Technical Analysis
Negative
1.66
Price Trends
1.48
Negative
1.70
Negative
2.43
Negative
Market Momentum
-0.11
Positive
27.25
Positive
15.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNN, the sentiment is Negative. The current price of 1.66 is above the 20-day moving average (MA) of 1.32, above the 50-day MA of 1.48, and below the 200-day MA of 2.43, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 27.25 is Positive, neither overbought nor oversold. The STOCH value of 15.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMNN.
Imunon Risk Analysis
Imunon disclosed 4 risk factors in its most recent earnings report. Imunon reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Imunon Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $31.49M | -0.04 | -58.08% | ― | ― | 86.74% | |
46 Neutral | $11.37M | -0.73 | -87.41% | ― | ― | 59.81% | |
45 Neutral | $6.06M | -0.24 | -314.89% | ― | ― | 71.67% | |
42 Neutral | $102.04M | -1.23 | -116.86% | ― | -98.25% | 76.83% |
* Healthcare Sector Average
IMNN
Imunon
1.07
-3.95
-78.69%
KZIA
Kazia Therapeutics
8.81
2.00
29.37%
PHIO
Phio Pharmaceuticals
0.92
-1.26
-57.71%
GNPX
Genprex
2.69
-210.71
-98.74%
RNAZ
TransCode Therapeutics
1.63
-11.89
-87.94%
Imunon Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Imunon Introduces Series B Preferred to Restructure Debt
Positive
Sep 29, 2026
On June 2, 2026, Imunon entered into a securities purchase agreement with Streeterville Capital for Series A preferred stock and two secured promissory notes totaling $10.22 million, strengthening its financing base. On September 28, 2026, the par...
Business Operations and StrategyExecutive/Board Changes
Imunon Adopts New Equity-Based Executive Compensation Program
Neutral
Aug 11, 2026
Imunon, Inc. has approved new compensatory programs allowing certain executive officers to elect to receive a portion of their base salary in shares of common stock, with additional shares granted as an incentive tied to the elected stock portion....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.